Study of BC2027 for advanced solid tumors with GPC3
Part of Cancer clinical trials.
This trial tests a new drug called BC2027 for people with advanced solid tumors that have a protein called GPC3. If standard treatments have stopped working, are not available, or caused side effects, this study may offer a new option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have an advanced solid tumor that has a protein called GPC3.
- You have tried standard treatments that did not work or are not available to you.
- You are willing to provide a tumor tissue sample from a previous biopsy or agree to a new one.
- Your key organs (like blood, liver, kidneys) are working well enough based on blood tests.
- You are willing to use effective birth control if you are of childbearing age.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, VBC103, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink or slow the growth of these tumors.
This trial tests a new cell therapy called SN301A for people with advanced liver cancer that has a specific protein (GPC3) on the tumor cells. The goal is to see if this treatment can help when other treatments have stopped working.
This trial tests a new drug called BC3195 in people with advanced or metastatic solid tumors that have not responded to or cannot tolerate standard treatments. It aims to see if the drug is safe and effective for cancers that express a specific marker called CDH3.
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
This trial tests a new drug called GB268, which is designed to help your immune system fight cancer. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial is testing a new medicine, AZD9793, for people with advanced or metastatic solid tumors that have a specific marker called GPC3. The goal is to see if AZD9793 can help shrink or control the cancer.
Hear when a new Advanced Solid Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.